CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 15/3087% below fair value
$4.66−0.18 (-3.72%)
Close on Nov 13, 2026Market cap $363.22MP/E –Yield –
CorMedix operating margin
Operating margin is operating income as a percentage of revenue.
CorMedix's operating margin for the twelve months ending Sep 30, 2026 was 38.6%. For fiscal 2025 it was 48.2%, against -51.4% the year before. The highest annual figure on record is 48.2% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.2% | +99.6 |
| FY2024 | Dec 31, 2024 | -51.4% | +46768.5 |
| FY2022 | Dec 31, 2022 | -46819.9% | −31402.4 |
| FY2021 | Dec 31, 2021 | -15417.5% | −4039.1 |
| FY2020 | Dec 31, 2020 | -11378.4% | −3962.1 |
| FY2019 | Dec 31, 2019 | -7416.3% | −1165.9 |
| FY2018 | Dec 31, 2018 | -6250.4% | +3747.0 |
| FY2017 | Dec 31, 2017 | -9997.4% | +1051.4 |
| FY2016 | Dec 31, 2016 | -11048.8% | −3123.2 |
| FY2015 | Dec 31, 2015 | -7925.6% | −3222.3 |
| FY2014 | Dec 31, 2014 | -4703.3% | +240943.6 |
| FY2013 | Dec 31, 2013 | -245646.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -12.1% | −61.4 |
| Q2 FY2026 | Jun 30, 2026 | 42.1% | −7.1 |
| Q1 FY2026 | Mar 31, 2026 | 50.0% | −1.5 |
| Q4 FY2025 | Dec 31, 2025 | 46.0% | +4.5 |
| Q3 FY2025 | Sep 30, 2025 | 49.2% | +77.9 |
| Q2 FY2025 | Jun 30, 2025 | 49.2% | +1947.3 |
| Q1 FY2025 | Mar 31, 2025 | 51.5% | +28296.2 |
| Q4 FY2024 | Dec 31, 2024 | 41.4% | +102167.5 |
| Q3 FY2024 | Sep 30, 2024 | -28.7% | +38744.4 |
| Q2 FY2024 | Jun 30, 2024 | -1898.1% | +90196.7 |
| Q4 FY2022 | Dec 31, 2022 | -28244.7% | −14449.7 |
| Q3 FY2022 | Sep 30, 2022 | -102126.1% | −79638.9 |
| Q2 FY2022 | Jun 30, 2022 | -38773.1% | +33040.2 |
| Q1 FY2022 | Mar 31, 2022 | -92094.8% | −83925.3 |
| Q4 FY2021 | Dec 31, 2021 | -13794.9% | −2873.7 |
| Q3 FY2021 | Sep 30, 2021 | -22487.2% | −15387.9 |
| Q2 FY2021 | Jun 30, 2021 | -71813.3% | −17561.6 |
| Q1 FY2021 | Mar 31, 2021 | -8169.5% | −591.6 |
| Q4 FY2020 | Dec 31, 2020 | -10921.2% | +10774.8 |
| Q3 FY2020 | Sep 30, 2020 | -7099.3% | +1588.0 |
| Q2 FY2020 | Jun 30, 2020 | -54251.7% | −38550.0 |
| Q1 FY2020 | Mar 31, 2020 | -7577.9% | −4570.3 |
| Q4 FY2019 | Dec 31, 2019 | -21696.0% | −29757.8 |
| Q3 FY2019 | Sep 30, 2019 | -8687.2% | −5938.0 |
| Q2 FY2019 | Jun 30, 2019 | -15701.7% | +97821.7 |
| Q1 FY2019 | Mar 31, 2019 | -3007.6% | +40890.8 |
| Q4 FY2018 | Dec 31, 2018 | 8061.8% | +19162.0 |
| Q3 FY2018 | Sep 30, 2018 | -2749.3% | +10369.0 |
| Q2 FY2018 | Jun 30, 2018 | -113523.4% | −108366.1 |
| Q1 FY2018 | Mar 31, 2018 | -43898.4% | −24638.6 |
| Q4 FY2017 | Dec 31, 2017 | -11100.2% | −5786.9 |
| Q3 FY2017 | Sep 30, 2017 | -13118.2% | – |
| Q2 FY2017 | Jun 30, 2017 | -5157.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -19259.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -5313.2% | – |
See a number that looks wrong?